BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2018-10-05 07:00 |
BerGenBio enters second stage of phase II trial with selective AXL inhibitor be…
|
English | 6.7 KB | ||
| 2018-09-25 14:00 |
BerGenBio: Updated phII clinical data with selective AXL inhibitor bemcentinib …
|
English | 13.9 KB | ||
| 2018-09-13 15:00 |
BerGenBio ASA: Notice of Arbitration with Rigel Pharmaceuticals, Inc.
|
English | 2.3 KB | ||
| 2018-09-05 07:00 |
BerGenBio to present interim phase 2 clinical data with selective AXL inhibitor…
|
English | 8.3 KB | ||
| 2018-08-30 07:00 |
BerGenBio to Present at the 20th Annual Global Investment Conference in New Yor…
|
English | 3.9 KB | ||
| 2018-08-29 10:56 |
BerGenBio ASA - Approval and publication of prospectus regarding listing of sha…
|
English | 5.6 KB | ||
| 2018-08-21 05:00 |
BerGenBio ASA: Results for the Second Quarter and First Half 2018
|
English | 59.2 KB | ||
| 2018-08-21 05:00 |
BerGenBio ASA: Results for the Second Quarter and First Half 2018
|
English | 1.5 MB | ||
| 2018-08-21 05:00 |
BerGenBio ASA: Results for the Second Quarter and First Half 2018
|
English | 4.2 MB | ||
| 2018-08-21 05:00 |
BerGenBio ASA: Results for the Second Quarter and First Half 2018
|
English | 7.5 KB | ||
| 2018-08-14 06:00 |
BerGenBio ASA: Invitation to Second Quarter and First Half 2018 Results Present…
|
English | 2.1 KB | ||
| 2018-06-26 06:15 |
Selective AXL inhibitor bemcentinib meets pre-specified efficacy endpoint in st…
|
English | 58.0 KB | ||
| 2018-06-26 06:15 |
Selective AXL inhibitor bemcentinib meets pre-specified efficacy endpoint in st…
|
English | 8.8 KB | ||
| 2018-06-18 07:46 |
BerGenBio: Posters presented at Congress of European Hematology Association (EH…
|
English | 28.8 KB | ||
| 2018-06-18 07:46 |
BerGenBio: Posters presented at Congress of European Hematology Association (EH…
|
English | 1.5 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
